FibroBiologics, Inc. Common Stock (FBLG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, FibroBiologics, Inc. Common Stock (FBLG) has a cash flow conversion efficiency ratio of -31.776x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.97 Million) by net assets ($125.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See FBLG equity financing ratio to measure how much of total assets are equity-financed.
FibroBiologics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how FibroBiologics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of FibroBiologics, Inc. Common Stock to evaluate the quality of earnings relative to operating cash generation.
FibroBiologics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FibroBiologics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quest Resource Holding Corp
NASDAQ:QRHC
|
0.005x |
|
Viscount Mining Corp.
V:VML
|
-0.022x |
|
Gabungan AQRS Bhd
KLSE:5226
|
-0.112x |
|
Planet Green Holdings Corp
NYSE MKT:PLAG
|
0.211x |
|
Panagene Inc
KQ:046210
|
0.001x |
|
Foremost Lithium Resource & Technology Ltd. Common stock
NASDAQ:FMST
|
-0.050x |
|
Only World Group Holdings Bhd
KLSE:5260
|
0.074x |
|
NanoRepro AG
XETRA:NN6
|
0.055x |
Annual Cash Flow Conversion Efficiency for FibroBiologics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of FibroBiologics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see FBLG market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $2.73 Million | $-11.90 Million | -4.351x | +14.82% |
| 2024-06-30 | $1.25 Million | $-6.40 Million | -5.109x | -602.06% |
| 2023-06-30 | $-4.00 Million | $-4.07 Million | 1.018x | -6.91% |
| 2022-06-30 | $-1.29 Million | $-1.41 Million | 1.093x | -- |
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.